"Cytochrome P-450 CYP2C9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 subtype that has specificity for acidic XENOBIOTICS. It oxidizes a broad range of important clinical drugs that fall under the categories of NONSTEROIDAL ANTI-INFLAMMATORY AGENTS; HYPOGLYCEMIC AGENTS; ANTCOAGULANTS; and DIURETICS.
| Descriptor ID |
D065729
|
| MeSH Number(s) |
D08.244.453.491.500.500 D08.811.682.690.708.170.450.500.500 D12.776.422.220.453.491.500.500
|
| Concept/Terms |
Cytochrome P-450 CYP2C9- Cytochrome P-450 CYP2C9
- CYP2C9, Cytochrome P-450
- Cytochrome P 450 CYP2C9
- P-450 CYP2C9, Cytochrome
- Cytochrome P450 PB-1
- Cytochrome P450 PB 1
- P450 PB-1, Cytochrome
- PB-1, Cytochrome P450
- Cytochrome P450 MP-4
- Cytochrome P450 MP 4
- MP-4, Cytochrome P450
- P450 MP-4, Cytochrome
- Cytochrome P450 MP-8
- Cytochrome P450 MP 8
- MP-8, Cytochrome P450
- P450 MP-8, Cytochrome
- CYP2C9
- CYPIIC9
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C9".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C9".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C9" by people in this website by year, and whether "Cytochrome P-450 CYP2C9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 3 | 3 |
| 2015 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C9" by people in Profiles.
-
Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. J Clin Pharmacol. 2019 12; 59(12):1632-1640.
-
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. Clin Pharmacol Ther. 2019 06; 105(6):1477-1491.
-
Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. J Thromb Haemost. 2017 04; 15(4):735-743.
-
Effect of CYP2C9 and VKORC1 Gene Variants on Warfarin Response in Patients with Continuous-Flow Left Ventricular Assist Devices. ASAIO J. 2016 Sep-Oct; 62(5):558-64.
-
Phenytoin toxicity in two-month-old Thai infant with CYP2C9 gene polymorphism--A case report. Brain Dev. 2016 Jan; 38(1):136-8.
-
Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms. Drug Metab Dispos. 2015 Jul; 43(7):1084-90.
-
Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics. 2015; 16(3):217-25.
-
Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. Transl Res. 2015 Jun; 165(6):651-7.
-
Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics J. 2014 Jun; 14(3):223-8.
-
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013 Aug 31; 382(9894):790-6.